Dr. Ehdaie weighs in on focal therapy with MRgFUS for GG2/3 prostate cancer

In this video, Behfar Ehdaie, MD, MPH, compared magnetic resonance (MR)–guided focused ultrasound (MRgFUS) with other forms of focal therapy used to treat prostate cancer as well as the learning curve associated with this specific therapy.

During the 2021 AUA Annual Meeting, Ehdaie presented a study showing that in some men with intermediate-risk prostate cancer, MRgFUS focal therapy may be an effective alternative to radical therapy that improves quality-of-life measures such as sexual function and urinary incontinence.

Ehdaie is an assistant member of the urology service department of surgery at Memorial Sloan Kettering Cancer Center, New York City, New York.